Neurological Disease: Early-Stage R&D and Dealmaking

Published by	Decision Resources, Inc.
Published	August, 2009	Product code	98548
Content info	25 Pages
Price	US $ 3450 PDF by E-mail (Global License)

Introduction
Related Reports

Neurological Disease: Early-Stage R&D and Dealmaking published by Decision Resources, Inc. in August, 2009. This report consists of 25 Pages and the price starts from US $ 3450.

Introduction

Abstract

Introduction

How can early-stage R&D efforts be positioned to tap the remaining opportunity in the neurology drug market? Although brimming with potential, neurology drug development is also rife with unique challenges that many companies and agents have been unable to overcome, as witnessed by the failures of agents initially deemed highly promising. However, careful planning - including risk mitigation through strategic collaboration - can allow a drug developer to take advantage of the significant opportunity in this market.

Questions Answered in This Report

Although therapies are available for neurological disorders, most of these conditions remain undertreated, and no cures are available. What benefits do novel therapies have over existing treatment options? How can companies mitigate the risk associated with drug development?
Much of the innovation in drug discovery and design occurs in small companies. What companies are developing novel approaches to treat neurological diseases? What collaborations have they forged with Big Pharma?
The neurology market is entering a period of stagnation. What is currently driving market growth? What are the greatest needs in the treatment of neurological diseases?

Scope

Novel targets for neurology: Beta-amyloid, beta-secretase, tau protein, NMDA, nicotinic acetylcholinesterase receptor, HMG-CoA reductase.
Novel technologies for neurology: Deep-brain stimulation, stem cell therapy.
Focus on diseases with neuronal degradation as a primary symptom: Alzheimer' s disease (AD), mild cognitive impairment (MCI), multiple sclerosis (MS), Parkinson' s disease (PD), Huntington' s disease (HD), ALS and other motor neuron diseases.
Company profiles: Lundbeck, CoMentis, Targacept, Vitae Pharmaceuticals.
Outlook: Challenges in drug development, recent dealmaking, need for increased research, benefits of academic collaborations.

Mentioned in This Report

Companies

Abbott
AC Immune
Acorda Therapeutics
Affiris
Allon Therapeutics
Apitope International
Astellas Pharma
AstraZeneca
Athersys
Bayer
Bial
Biogen Idec
Biovail
Boehringer Ingelheim
BrainStorm Cell Therapeutics
Cambridge Laboratories
CoMentis
Cytos Biotechnology
Eisai
Elan
Eli Lilly
Envivo
Evotec
Genentech
Geron
GlaxoSmithKline
Intellect Neurosciences
Johnson & Johnson
LifeHealth
Lundbeck
Medivation
Merck & Co.
Merck Serono
MorphoSys
Neureva
NeuroSearch
Novartis
Ovation Pharmaceuticals
Peptimmune
Pfizer
Prana Biotechnology
QR Pharma
ReceptoPharm
ReNeuron Group
Roche
Stem Cell Therapeutics
StemCells
Targacept
TauRx Therapeutics
Vitae Pharmaceuticals
Wyeth

Executive Summary
Strategic Considerations
Stakeholder Implications
Introduction
Neurology Market: Poised for Change and Innovation
Novel Approaches to Neurological Disease Treatment
Novel Targets
Beta-Amyloid
Beta-Secretase
Tau Protein
NMDA
Nicotinic Receptors
HMG-CoA Reductase
Novel Technologies
Stem Cell Therapy
Deep-Brain Stimulation
Company Profiles
Lundbeck
CoMentis
Targacept
Vitae Pharmaceuticals
Outlook

Tables

1. Descriptions of Select Neurological Diseases
2. Top-Selling Products for the Treatment of Neurological Diseases, 2008
3. Beta-Amyloid Agents in Clinical Development for the Treatment of Neurological Diseases
4. Beta-Secretase Agents in Clinical Development for the Treatment of Neurological Diseases
5. Tau Protein Agents in Clinical Development for the Treatment of Neurological Diseases
6. NMDA Agents in Clinical Development for the Treatment of Neurological Diseases
7. Nicotinic Receptor Agents in Clinical Development for the Treatment of Neurological Diseases
8. Benefits and Drawbacks of Stem Cell Types in the Treatment of Neurological Diseases
9. Select Companies Developing Stem Cell Therapies
10. Select Deals Focusing on the Development of Neurological Disease Treatments